# Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia

Study · id `cardio:ct-nct04438096` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04438096](<https://clinicaltrials.gov/study/NCT04438096>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04438096

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04438096. Randomized; quadruple masking; primary purpose treatment. Start 2020-07-15 (anticipated); primary completion 2021-12-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04438096, source copy `cardio:ctgov-nct04438096-2020-06-23`, retrieved 2026-10-31)
- Planned start: 2020-07-15 (anticipated) (ClinicalTrials.gov record NCT04438096, source copy `cardio:ctgov-nct04438096-2020-06-23`, retrieved 2026-10-31)
- Primary completion: 2021-12-15 (anticipated) (ClinicalTrials.gov record NCT04438096, source copy `cardio:ctgov-nct04438096-2020-06-23`, retrieved 2026-10-31)
- Completion: 2022-03-15 (anticipated) (ClinicalTrials.gov record NCT04438096, source copy `cardio:ctgov-nct04438096-2020-06-23`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04438096, source copy `cardio:ctgov-nct04438096-2020-06-23`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04438096-2020-06-23`, retrieved 2026-10-31)

## The registry's words

- Brief title: Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia
- Condition: Hyperlipidemia
- Intervention (Drug): 100 mg
- Intervention (Drug): 200 mg
- Intervention (Drug): 300 mg
- Intervention (Drug): Placebo
- Lead sponsor: CVI Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

## Provenance

Content hash: 8e8f35a9dd0466d368a54a4d56d7df0e871c0657364c4253fb3d5425ed6fe0ba
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
